Communiqués Kiora Pharmaceuticals, Inc.

Actions

EYEG

US49721T5074

Temps Différé Nasdaq Autres places de cotation 15:42:41 16/07/2024			Varia. 5j.	Varia. 1 janv.
4,17 ^USD	+1,21 %		-5,22 %	-11,30 %

02/07	Kiora Pharmaceuticals, Inc. annonce des changements au sein de son conseil d'administration et de ses comités	CI
25/06	Kiora Pharmaceuticals nomme Roger A. Goldberg à son conseil scientifique	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024, Kiora Invites Investors to Submit Questions Following the Conference Presentation	11/07	AQ
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation	10/07	NE
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals Board of Directors	02/07	AQ
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors	01/07	NE
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences	20/05	NE
Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease	13/05	AQ
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease	10/05	NE
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference	08/05	NE
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa	06/05	NE
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	12/04	AQ
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	11/04	NE
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	05/04	NE
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	28/03	NE
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	25/03	NE
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	08/03	NE
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01/02	NE
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	31/01	NE
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301	17/11	AQ
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa	09/11	NE
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa	04/11	NE

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kiora Pharmaceuticals, Inc.

Actions

EYEG

US49721T5074

Communiqués

Filtres